Cancer-Related Fatigue

Physical Medicine and Rehabilitation Clinics of North America

Volumn 20, Issue 2, 2009, Pages 405-416

  Cheville, Andrea L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer; Exercise; Fatigue; Review; Symptom

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARNITINE; MEGESTROL ACETATE; METHYLPHENIDATE; METHYLPREDNISOLONE; MODAFINIL; PAROXETINE; PLACEBO; PREDNISONE;

ANOREXIA; ANXIETY; BREAST CANCER; CANCER FATIGUE; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONFUSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; HEADACHE; HUMAN; INSOMNIA; KINESIOTHERAPY; MORBIDITY; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RATING SCALE; REVIEW; SIDE EFFECT; TACHYCARDIA; TREMOR;

DISABILITY EVALUATION; FATIGUE; HUMANS; INCIDENCE; NEOPLASMS; UNITED STATES;

EID: 64749112937     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmr.2008.12.005     Document Type: Review

References (71)

1. Curt G.A., Breitbart W., Cella D., et al. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 5 5 (2000) 353-360
2. Hofman M., Ryan J.L., Figueroa-Moseley C.D., et al. Cancer-related fatigue: the scale of the problem. Oncologist 12 Suppl 1 (2007) 4-10
3. Mock V., Atkinson A., Barsevick A., et al. NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 14 11A (2000) 151-161
4. World Health Organization. International statistical classification of diseases and related health problems 1989 revision (2003), World Health Organization, Geneva
5. Ahlberg K., Ekman T., Gaston-Johansson F., et al. Assessment and management of cancer-related fatigue in adults. Lancet 362 9384 (2003) 640-650
6. Morrow G.R., Hickok J.T., Andrews P.L., et al. Reduction in serum cortisol after platinum based chemotherapy for cancer: a role for the HPA axis in treatment-related nausea?. Psychophysiology 39 4 (2002) 491-495
7. Morrow G.R., Andrews P.L., Hickok J.T., et al. Fatigue associated with cancer and its treatment. Support Care Cancer 10 5 (2002) 389-398
8. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25 3 Suppl 7 (1998) 43-46
9. Miaskowski C. The need to assess multiple symptoms. Pain Manag Nurs 3 4 (2002) 115
10. Ryan J.L., Carroll J.K., Ryan E.P., et al. Mechanisms of cancer-related fatigue. Oncologist 12 Suppl 1 (2007) 22-34
11. Schwartz A.L., Nail L.M., Chen S., et al. Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest 18 1 (2000) 11-19
12. Hickok J.T., Roscoe J.A., Morrow G.R., et al. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer 104 8 (2005) 1772-1778
13. Lawrence D.P., Kupelnick B., Miller K., et al. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monographs 32 (2004) 40-50
14. Mustian K.M., Morrow G.R., Carroll J.K., et al. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist 12 Suppl 1 (2007) 52-67
15. Fobair P., Hoppe R.T., Bloom J., et al. Psychosocial problems among survivors of Hodgkin's disease. J Clin Oncol 4 5 (1986) 805-814
16. Prue G., Rankin J., Allen J., et al. Cancer-related fatigue: a critical appraisal. Eur J Cancer 42 7 (2006) 846-863
17. Mormont M.C., Waterhouse J., Bleuzen P., et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6 8 (2000) 3038-3045
18. Mendoza T.R., Wang X.S., Cleeland C.S., et al. The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer 85 5 (1999) 1186-1196
19. Yellen S.B., Cella D.F., Webster K., et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13 2 (1997) 63-74
20. McNair Dm L.M., and Droppleman L.F. Profile of mood states. [Revised] (1992), EdITS/Educational and Industrial Testing Service, San Diego (CA)
21. Piper B.F., Dibble S.L., Dodd M.J., et al. The revised piper fatigue scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 25 4 (1998) 677-684
22. Smets E.M., Garssen B., Bonke B., et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39 3 (1995) 315-325
23. Davidson J.R., MacLean A.W., Brundage M.D., et al. Sleep disturbance in cancer patients. Soc Sci Med 54 9 (2002) 1309-1321
24. Bower J.E. Prevalence and causes of fatigue after cancer treatment: the next generation of research. J Clin Oncol 23 33 (2005) 8280-8282
25. Stone P., Richards M., A'Hern R., et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11 5 (2000) 561-567
26. Given B., Given C.W., McCorkle R., et al. Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum 29 6 (2002) 949-956
27. Bohlius J., Weingart O., Trelle S., et al. Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nat Clin Pract Oncol 3 3 (2006) 152-164
28. Curt G.A. Impact of fatigue on quality of life in oncology patients. Semin Hematol 37 4 Suppl 6 (2000) 14-17
29. Oldervoll L.M., Kaasa S., Knobel H., et al. Exercise reduces fatigue in chronic fatigued Hodgkin's disease survivors-results from a pilot study. Eur J Cancer 39 1 (2003) 57-63
30. Lucca U., Tettamanti M., Mosconi P., et al. Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the "Health and Anemia" study. PLoS ONE 3 4 (2008) e1920
31. Turner R., Anglin P., Burkes R., et al. Epoetin alfa in cancer patients: evidence-based guidelines. J Pain Symptom Manage 22 5 (2001) 954-965
32. Rizzo J.D., Somerfield M.R., Hagerty K.L., et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26 1 (2008) 132-149
33. Chao C.C., Gallagher M., Phair J., et al. Serum neopterin and interleukin-6 levels in chronic fatigue syndrome. J Infect Dis 162 6 (1990) 1412-1413
34. Patarca R., Klimas N.G., Lugtendorf S., et al. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis 18 Suppl 1 (1994) S147-S153
35. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 1 (2003) 35-45
36. Pusztai L., Mendoza T.R., Reuben J.M., et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokines 25 3 (2004) 94-102
37. Fernstrom J.D., and Fernstrom M.H. Exercise, serum free tryptophan, and central fatigue. J Nutr 136 2 (2006) 553S-559S
38. Bailey S.P., Davis J.M., and Ahlborn E.N. Effect of increased brain serotonergic activity on endurance performance in the rat. Acta Physiol Scand 145 1 (1992) 75-76
39. Badawy A.A., Morgan C.J., Llewelyn M.B., et al. Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome. J Psychopharmacol 19 4 (2005) 385-391
40. Morrow G.R., Hickok J.T., Roscoe J.A., et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester cancer center community clinical oncology program. J Clin Oncol 21 24 (2003) 4635-4641
41. Roscoe J.A., Morrow G.R., Hickok J.T., et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 89 3 (2005) 243-249
42. Bower J.E., Ganz P.A., Aziz N., et al. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 64 4 (2002) 604-611
43. Bower J.E., Ganz P.A., and Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med 67 2 (2005) 277-280
44. Bower J.E., Ganz P.A., Dickerson S.S., et al. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 30 1 (2005) 92-100
45. Mormont M.C., De Prins J., and Levi F. [Study of circadian rhythms of activity by actometry: preliminary results in 30 patients with metastatic colorectal cancer]. [French]. Pathol Biol (Paris) 44 3 (1996) 165-171
46. Mormont M.C., Hecquet B., Bogdan A., et al. Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int J Cancer 78 4 (1998) 421-424
47. Rich T., Innominato P.F., Boerner J., et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11 5 (2005) 1757-1764
48. Roscoe J.A., Morrow G.R., Hickok J.T., et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 10 4 (2002) 329-336
49. (NCCN) Nccn. Clinical practice guidelines in oncology: cancer-related fatigue, v1. Available at: (Accessed November 30, 2008). http://www.nccn.org/professionals/physician_glf/PDF/fatigue.pdf
50. Bruera E., Driver L., Barnes E.A., et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 21 23 (2003) 4439-4443
51. Sarhill N., Walsh D., Nelson K.A., et al. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 18 3 (2001) 187-192
52. Homsi J., Nelson K.A., Sarhill N., et al. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care 18 6 (2001) 403-407
53. Hanna A., Sledge G., Mayer M.L., et al. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer 14 3 (2006) 210-215
54. Schwartz A.L., Thompson J.A., and Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 29 7 (2002) E85-90
55. Bruera E., Valero V., Driver L., et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 24 13 (2006) 2073-2078
56. Lower E, Fleishman S, Cooper A, et al. A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as a new treatment of fatigue and "chemobrain" in adult cancer patients. J Clin Oncol 2005 [ASCO] Meeting Abstract 8000.
57. Morrow G.R., Gillies LJ O.W., Hickok J.T., et al. The positive effect of the psycho-stimulant modafinil on fatigue from cancer that persists after treatment is completed. J Clin Oncol (2005) [ASCO Meeting Abstract 8012]
58. Kaleita T.A., Wellisch D.K., Graham C.A., et al. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. J Clin Oncol (2006) [ASCO Meeting Abstract 1503]
59. Cullum J.L., Wojciechowski A.E., Pelletier G., et al. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry 49 2 (2004) 139-144
60. Moss E.L., Simpson J.S., Pelletier G., et al. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology 15 3 (2006) 259-267
61. Bruera E., Roca E., Cedaro L., et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69 7-8 (1985) 751-754
62. Bruera E., Ernst S., Hagen N., et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 2 2 (1998) 74-78
63. Tannock I., Gospodarowicz M., Meakin W., et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7 5 (1989) 590-597
64. Gramignano G., Lusso M.R., Madeddu C., et al. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 22 2 (2006) 136-145
65. Graziano F., Bisonni R., Catalano V., et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer 86 12 (2002) 1854-1857
66. Cruciani R.A., Dvorkin E., Homel P., et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci 1033 (2004) 168-176
67. McNeely M.L., Campbell K.L., Rowe B.H., et al. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ 175 1 (2006) 34-41
68. Courneya K.S., Friedenreich C.M., Quinney H.A., et al. A randomized trial of exercise and quality of life in colorectal cancer survivors. Eur J Cancer Care (Engl) 12 4 (2003) 347-357
69. Segal R.J., Reid R.D., Courneya K.S., et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21 9 (2003) 1653-1659
70. Campbell A., Mutrie N., White F., et al. A pilot study of a supervised group exercise programme as a rehabilitation treatment for women with breast cancer receiving adjuvant treatment. Eur J Oncol Nurs 9 1 (2005) 56-63
71. Brown P., Clark M.M., Atherton P., et al. Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer?. Am J Clin Oncol 29 1 (2006) 52-58